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Abstract
Background: In the biochemical milieu of human colon, bile acids act as signaling mediators between the host
and its gut microbiota. Biotransformation of primary to secondary bile acids have been known to be involved in
the immune regulation of human physiology. Several 16S amplicon-based studies with inflammatory bowel disease
(IBD) subjects were found to have an association with the level of fecal bile acids. However, a detailed investigation
of all the bile salt biotransformation genes in the gut microbiome of healthy and IBD subjects has not been performed.
Results: Here, we report a comprehensive analysis of the bile salt biotransformation genes and their distribution at the
phyla level. Based on the analysis of shotgun metagenomes, we found that the IBD subjects harbored a significantly
lower abundance of these genes compared to the healthy controls. Majority of these genes originated from Firmicutes
in comparison to other phyla. From metabolomics data, we found that the IBD subjects were measured with a
significantly low level of secondary bile acids and high levels of primary bile acids compared to that of the healthy
controls.
Conclusions: Our bioinformatics-driven approach of identifying bile salt biotransformation genes predicts the bile salt
biotransformation potential in the gut microbiota of IBD subjects. The functional level of dysbiosis likely contributes to
the variation in the bile acid pool. This study sets the stage to envisage potential solutions to modulate the
gut microbiome with the objective to restore the bile acid pool in the gut.
Keywords: Secondary bile acids, Gut microbiota, IBD, Bioinformatics, Metagenomics, Metabolomics, And bile
salt biotransformation genes
Background
Microbial modification of human-derived bile acids
(BAs) is known as secondary BAs, which provide cross-
talk between the human host and gut bacteria in the
large intestine [1]. Primary BAs such as cholic acid (CA)
and chenodeoxycholic acid (CDCA) that are produced
in the liver are modified to deoxycholic acid (DCA) and
lithocholic acid (LCA) in the colon respectively. These
secondary BAs have been known to regulate several host
metabolic processes via receptor signaling, including the
farnesoid X receptor (FXR), the liver X receptor (LXR),
the G-protein coupled receptor TGR5, and the vitamin
D receptor present in the gut, the liver and in the per-
iphery [2]. Concerning the anti-inflammatory and anti-
microbial functions exerted by the secondary BAs, dys-
biosis in the bile salt biotransformation potential of gut
microbiota might influence the function of BAs in the
host physiology.
Previous studies of small-sized cohorts or 16S amplicon
based studies have identified significant differences in the
fecal metabolites between the healthy and Inflammatory
Bowel Disease (IBD) subjects [3–6]. From a growing body
of evidence, two well-established IBD-associated taxo-
nomic signatures have been observed: (i) phylum-level de-
crease in Firmicutes (especially of class Clostridia and
family Lachnospiraceae), and (ii) phylum-level increase in
Proteobacteria (especially of family Enterobacteriaceae)
[7]. At metabolite level, mouse-models of inflammation
were measured with a significant reduction of gut
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microbiota-derived bile acids [8–10]. This decrease has re-
sulted in an altered pathophysiological response in the
host via an altered-composition of the gut microbiome.
However, the extent of secondary BA metabolism by
the gut microbiota remains less studied as the bacterial
species that are specialized with bile acid metabolic
genes have been characterized and studied in only few
Clostridium species [11–14]. Furthermore, so far only a
few of the enzymatic genes comprising the entire path-
way of BA metabolism had been assessed from shotgun
metagenomic sequences [15, 16]. None of the previous
studies provided a complete picture considering all the
relevant enzymatic genes, on the secondary bile acid me-
tabolism, i.e., their prevalence in other bacterial species
and abundances under different health states.
Henceforth, we sought to investigate secondary BA
pathway-related protein and gene sequences based on
sequence and structural domain conservation. Once they
have been screened, estimation of these sequences from
the shotgun metagenomes would allow predicting the
bile acid metabolic potential in a microbial community.
Based on this approach, the following research questions
were formulated: (i) What is the distribution profile of
bile salt biotransformation protein (BSBP) homologs at
phyla level? (ii) How are these BSBP homologs prevalent
at strain level? (iii) How conserved or divergent these
homologous protein sequences are with respect to the
phylum and enzymatic category? (iv) Does the abun-
dance of bile salt biotransformation genes (BSBGs) vary
among the fecal metagenomes of similar group and be-
tween different groups? and (v) Could parallel observa-
tions be deduced at metabolite level based on the
findings from gene abundance estimation?
Results
To provide a comprehensive view on gut microbial-
mediated bile acid metabolism, the following analyses
were performed: (i) Identification of BSBP homologs in
microbial strains and their distribution at phyla level; (ii)
Analysis of protein-sequence similarity network (PSSN)
of identified homologs for each enzymatic function; (iii)
Quantitative comparison of BSBG abundances between
healthy controls and IBD subjects; (iv) Phylum-level
quantitative comparison of BSBG abundances between
healthy controls and IBD subjects, and (v) Quantitative
comparison of fecal bile acid metabolites between
healthy controls and IBD subjects.
Identification and distribution of bile salt
biotransformation protein homologs
To identify BSBP homologs, BSBP sequences from Clos-
tridium scindens were deployed as reference query se-
quences (Additional file 1: Table S1). The reasons for
considering this species as reference are: (i) limited
experimental data (in testing the bacterial growth sensi-
tivity to BAs) or lack in availability of BSBP or BSBG
reference dataset (like an ARG database for antibiotic-
resistance genes) [17], and (ii) extensive characterization
of enzymatic genes comprising the secondary bile acid
metabolic pathway (as shown to be encoded by bai
operon) in the species C. scindens [13, 14, 18]. Through
sensitivity-specificity analysis and user-defined methods
of criteria to select the optimal parameters (Additional
file 1: Table S2 and S4), it was ensured that the selected
sequences were true positive homologs and rejected
sequences that were false positive and true negative
homologs. Therefore, based on protein sequence and do-
main conservation, a total of 10,613 protein homologs
were identified. These counts of protein sequences were
distributed based on the phyla and enzyme-homology
(Table 1).
Based on the taxonomic origin (i.e., at strain level) of
protein sequences, all the identified protein homologs
were inspected for the presence and absence of each
functional enzyme category as presented in Add-
itional file 2: Table S1. Microbial strains that were preva-
lent for more than half of the enzyme categories were
shown in Fig. 1. From the presence and absence heat-
map (Fig. 1), we observed that species from the same
genus had a similar profile pattern of BSBP homologs.
Moreover, in a majority of the species, the distribution
pattern of these enzymatic sequences was not as similar
to that in the reference bai operon from C. scindens
(Additional file 2: Table S1). Microbial strains of Lacto-
bacillus species were known to deconjugate bile salts
[19, 20], and we observed the same with prevalence for
BSH homologs. However, enteric pathogens like Shigella,
Salmonella, and Klebsiella were prevalent for Bai-like
proteins but not for BSH homolog. (Additional file 2:
Table S1).
Protein-sequence similarity network of bile salt
biotransformation protein homologs
Next, to evaluate the genetic diversity of identified ho-
mologs at the phylum level, protein sequences from each
enzyme category were analyzed using sequence-based
similarity network (Fig. 2). For a multiple sequence
alignment (for at least thousands of sequences), the low
resolution of nodes is often encountered due to a low
number of informative phylogenetic sites [21]. Hence, to
overcome this challenge, we performed the following
analysis. In a PSSN, the number of cluster formation
would differ based on the threshold value, such as there
would be fewer clusters for relaxed threshold value and
more clusters for stringent threshold value. The optimal
threshold value for each network shown in Fig. 2 is pro-
vided in Additional file 1: Table S4. From a broad per-
spective, we observed that sequences from similar
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phylum were co-localized on the network, with minor
exceptions where sequences from different phylum were
clustered together.
However, on a detailed level of inspection, BaiCD/H
showed a single cluster even at higher stringent edge
thresholds in comparison to the optimal values of other
networks, which denotes less divergence within these
homologous sequences across diverse phylum. While for
the other networks, there was a variation in the number
of clusters from a range of relaxed to stringent threshold
criteria (Fig. 2 and Additional file 1: Table S4). For in-
stance, a network for BaiG and BaiA/L (enzyme category
with few protein connections or more clusters) identifies
farther sequence divergence among the putative homo-
logs. For each enzyme category, even though these pro-
tein homologs were identified through sequence
conservation to a reference sequence, the clustering
pattern reveals the biological degree of divergence or
convergence among the identified homologs at their
phyla-level.
Comparative metagenomic analysis of bile salt
biotransformation gene abundances between healthy and
IBD subjects
Through investigation of gene abundances (for the iden-
tified list of protein homologs, as described in the
Methods section) in the fecal metagenomes, bile salt bio-
transformation potential was compared quantitatively in
the gut microbiota of healthy and IBD subjects.
In the METAHIT-Spanish cohort, on comparing
the normalized gene abundance of total BSBGs
between healthy (n = 14) and IBD (n = 25) subjects,
we found a significant difference between the abun-
dance values of healthy and IBD subjects. The
results in Fig. 3a show that the mean of the normal-
ized abundance of BSBGs was lower in IBD subjects
(i.e., 7.77e-05) than that of healthy controls (i.e.,
1.08e-04) (Mann–Whitney–Wilcoxon test, p < 0.05),
suggesting lower potency of BA biotransformation in
the IBD subjects than that of the healthy controls.
Our results here were consistent with findings from
Table 1 Distribution of the total number of bile biotransformation protein homologs grouped by respective phylum
Phylum BaiA BaiB BaiCD BaiE BaiF BaiG BaiH BaiI BaiJ BaiK BaiL Bsh HSD
Actinobacteria 86 317 25 538 146 475 67 0 15 68 44 36 182
Bacteroidetes 158 1 2 1 0 1 2 0 3 0 23 4 264
Firmicutes 385 13 435 20 96 244 424 2 130 92 576 889 409
Fusobacteria 5 0 2 0 0 0 2 0 44 0 0 0 11
Proteobacteria 114 152 92 104 460 73 85 0 31 534 84 2 598
Verrucomicrobia 1 0 0 1 0 0 0 0 0 0 2 0 2
Fig. 1 Prevalence of bile salt biotransformation protein homologs in bacterial strains, where at least more than half of the reference proteins
were identified. The grey and blue color indicates the absence and presence of the protein homolog respectively
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similar analyses performed in Labbe et al. [22],
where samples from the MetaHIT cohort were also
analyzed. However, further statistical comparisons
between the subtypes of IBD subjects (i.e., Ulcerative
colitis (UC) and Crohn’s disease (CD)) could not be
performed due to an insufficient number of CD
samples.
In the iHMP-American cohort, on comparing the nor-
malized gene abundance of total BSBGs in the healthy
(n = 18) and IBD (n = 65) subjects, we could not find
any significant difference between the abundance values
of healthy and IBD subjects. However, on all possible
combination of statistical comparisons between the
healthy, UC and CD subjects, the results in Fig. 3b show
Fig. 2 Construction of sequence-based protein similarity network of each bile salt biotransformation enzyme homolog, where each node represents a
sequence, connected to another node as defined by an edge metric (which is optimal e-value and pairwise sequence identity of at least greater
than 30%)
A B
Fig. 3 Quantitative comparison of normalized abundance of total BSBGs between healthy and IBD individuals in (a). Spanish cohort, and (b). American
cohort. The shape refers to the kernel probability density of the data at different values. The boxplots inside the violin plot represent the interquartile
range between the first and third quartiles with the median line inside the boxes, whereas the whiskers indicate the minimum and maximum values
from the data distribution. The asterisks on the top indicate ns: p > 0.05, *: p < = 0.05, **: p < = 0.01, ***: p < = 0.001, ****: p < = 0.0001 (Mann-Whitney
Wilcoxon test). IBD subjects diagnosed with subtype Crohn’s disease and Ulcerative colitis is abbreviated as CD and UC respectively
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that the mean of normalized abundance of BSBGs was
lower in the CD subjects (i.e., 3.68e-05) than that of the
healthy controls (i.e., 4.34e-05) (Mann–Whitney–Wil-
coxon test, p < 0.05), suggesting lower potency of BA
biotransformation in the CD subjects than that of the
healthy controls. No significant differences were ob-
served between the following comparisons (i) healthy
and UC subjects, and (ii) UC and CD subjects.
Comparative metagenomic analysis of bile salt
biotransformation gene abundances among healthy
subjects from different countries
Similar to above, through investigation of gene abun-
dances (for the identified list of protein homologs) in the
fecal metagenomes, we compared the bile salt biotrans-
formation potential in the gut microbiota of healthy sub-
jects from three different countries, i.e., USA (n = 18),
Denmark (n = 86) and Spain (n = 14). Additional file 1:
Figure S2 revealed variation in the normalized abun-
dances of the total BSBGs. From all possible combin-
ation of pairwise comparisons among different
countries, we observed that the significant differences
among healthy individuals of different countries. While
individuals from the USA showed a significant difference
from that of Denmark and Spain (Mann Whitney Wil-
coxon, p < 0.01), no significant difference was found be-
tween the healthy individuals of Denmark and Spain.
These findings hint at the possibility of diet as an
important factor that could influence the composition of
the gut microbiota, thereby leading to the differences in
the abundance of BSBGs [23–25]. This analysis also
highlights the importance of considering demographic-
ally matched samples as a prerequisite for comparative
functional studies.
Taxonomic-level comparative metagenomic analysis of
bile salt biotransformation gene abundances between
healthy and IBD subjects
To evaluate the contribution of phyla accounting for
BSBG abundances, each mapped gene was retrieved for
its corresponding taxonomic lineage, and the normalized
abundances of taxonomic-level BSBGs were computed
accordingly for each group in both the cohort (Fig. 4).
The results show that the genes from Firmicutes phylum
accounted for the most considerable abundance for the
BSBG in comparison to other phyla (Mann-Whitney-
Wilcoxon test, p < 0.05). This observation, i.e., high
abundance of genes from the Firmicutes phylum, is
Fig. 4 Quantitative comparison of normalized abundance of taxonomic lineage-specific BSBGs between healthy and IBD individuals in American
cohort. The shape refers to the kernel probability density of the data at different values. The pointrange refers to the mean and error range value
of the data distribution. IBD subjects diagnosed with subtype Crohn’s disease and Ulcerative colitis is abbreviated as CD and UC respectively
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consistent with the existing literature, which states that
species from Firmicutes phylum dominate in BA metab-
olism [16]. However, lower abundance of Firmicutes
phylum-specific BSBGs in IBD subjects compared to
that of healthy controls further confirms one of the
typical IBD signature (i.e., marked by a decreased abun-
dance of species from Firmicutes) (Mann-Whitney-Wil-
coxon test, p < 0.05) [26–28]. Besides Firmicutes, BA
genes from Actinobacteria were found to be lower in
CD than in healthy controls (Mann-Whitney-Wilcoxon
test, p < 0.05) (Fig. 4). Furthermore, no significant differ-
ences were observed in the level of BSBGs for the phyla:
Bacteroidetes and Proteobacteria between the healthy
and IBD subjects.
The family-level and genus-level analysis of bile salt
biotransformation genes from Firmicutes phylum were
investigated among CD, UC subjects, and healthy con-
trols. As presented in Fig. 4, it is to be observed that
genes from Enterococcaceae, Eubacteriaceae, and Rumi-
nococcaceae were low in CD and UC subjects in com-
parison to healthy controls (Mann-Whitney-Wilcoxon
test, p < 0.05). However, genes from Clostridiaceae and
Eggerthellaceae, were found to be low in CD but not UC
subjects in comparison to healthy controls (Mann-Whit-
ney-Wilcoxon test, p < 0.05). Accordingly, genes from
genera Enterococcus, Eubacterium, and Ruminococcus
were found to be low in CD and UC subjects, while
genes from genera Clostridium and Coprococcus were
found to be low only in CD subjects than that of healthy
controls (Mann-Whitney-Wilcoxon test, p < 0.05). Simi-
lar findings were obtained when performed in the other
MetaHIT-Spanish IBD cohort (Additional file 1: Figure
S3). These findings highlight the association of gene ho-
mologs from these genera to bile salt biotransformation
potential in the context of IBD subjects, as supported in
a study where genus-level abundance were correlated to
bile acid levels in the feces of healthy donors [29].
Comparative fecal metabolomics analysis of bile acids
between healthy and IBD subjects
To verify if the IBD individuals have reduced levels of
secondary BAs corresponding to their predicted low
abundance of BSBGs than that of healthy controls,
metabolomics data from the iHMP cohort were ana-
lyzed. Fecal bile acid metabolites were measured in LC-
MS (C18 negative ion mode analysis) [30, 31]. To com-
pare the bile acid profile between healthy and subtypes
(CD and UC) of IBD subjects, quantification of BAs was
expressed in proportion, where the level of each BA was
calculated to the total level of BAs. Figure 5 shows the
proportion of a wide range of primary and secondary
BAs, both in conjugated and unconjugated forms. The
major BAs, cholate (primary BA) and deoxycholate and
lithocholate (secondary BAs), were found to be in high
and low levels in both the subtypes of IBD subjects than
that of healthy controls (Mann-Whitney-Wilcoxon test,
p < 0.05). The conjugated forms of primary BAs such as
glycocholate, taurocholate, and taurochenodeoxycholate
were found to be in high levels than healthy controls
(Mann-Whitney-Wilcoxon test, p < 0.05), which suggests
the lower abundance of genes encoding bile salt hydro-
lase [32, 33].
Furthermore, it was observed that there was a decrease
in the levels of secondary BAs in CD than that of healthy
controls. This decrease in the level of secondary BAs
compared to the increased level of primary BAs once
again suggests a decrease in the potency of BA biotrans-
formation, which is consistent with our comparative
metagenomic analysis. These results were in line with a
similar analysis performed on this cohort [30, 34].
Altogether, the proportions of different forms of conju-
gated and primary BAs were found at higher levels in
IBD subjects than that of healthy controls. These obser-
vations were congruent to that found in Duboc et al.
[35, 36] where low levels of secondary BAs were found
in IBD subjects, who were in the active phase and clin-
ical remission state.
Discussion
In this study, we performed bioinformatic analysis on
secondary bile acid metabolism and explored their abun-
dances in the whole-genome metagenomic sequences of
healthy and IBD subjects. The overall aim of this work
was to gain an understanding of the bile salt biotrans-
formation potential of the human gut microbiota. This
provided insights into how the change in the abundance
of BSBGs altered the level of BA metabolic profiles in a
dysbiotic state.
Based on the analyses that have been performed, we
highlight the following results resolving back to our for-
mulated objectives (i) BSBP homologs were prevalent
across abundant phyla, such as Bacteroidetes, Firmi-
cutes, Actinobacteria, and Proteobacteria. However,
phyla- and genera-level differential gene abundance ana-
lysis revealed dominant role of Firmicutes and its associ-
ated genera for BSBGs; (ii) The prevalence of BSBP
profile varied from a low to a high scale of spectrum;
(iii) PSSN revealed the degree of divergence for different
enzymatic categories; (iv) BSBG-specific quantitative
estimation of shotgun metagenomes suggests lower po-
tency of bile salt biotransformation in the gut microbiota
of IBD subjects; (v) Evaluation at metabolomics level re-
vealed parallel reduction of gut microbial-derived bile
acids in IBD subjects compared to healthy controls.
Homology-based detection of BSBP homologs suggests
three patterns as discussed: firstly, the presence of a par-
tial set of homologs in comparison to the whole set of
enzymatic categories might suggest a similar situation as
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found in C. hiradonis and C. sordellii. For instance, C.
hiradonis carried baiBCDEA2FGHJ while C. sordellii
carried only baiCDA2HE [37]. Alternatively, it could be
a possibility of similar function with similar substrates to
that of bile acid metabolism. Secondly, experimental ap-
proaches to elucidate the requirement for minimum bai
gene set could clear the specific distribution of these
genes across gut species. Thirdly, it is to be established
which combination of Bai and BSH protein contribute
to the phenotype of resistance or sensitivity to BAs, be-
cause, only a subset of species was found to carry BSH
homologs, while other species lacked in BSH homolog.
Extracellular enzymatic activities similar to BSH could
perhaps provide functional compensation for species
lacking the enzyme [38, 39].
Besides evaluation of BSBGs in IBD subjects, similar
dysbiosis has been observed in cirrhotic patients, where
a low-level input of primary BAs to the gut leads to a re-
duction of BA metabolizers in the large intestine. Ac-
cordingly, reduced levels of secondary BAs in the feces
and increased levels of primary BAs were found in the
serum and feces of cirrhotic patients [40–42]. As both
the cases converge to a similar metabolic phenotype, fur-
ther investigation at advanced level could avoid mis-
classification of these subjects. Contrarily, high
physiological levels of secondary BA have been associ-
ated with colorectal cancer patients [43]. Due to their
detergent-like properties, chronic exposure to higher
concentration of BAs can damage cell membrane and
induce pro-inflammatory pathways resulting in activa-
tion of ROS and genomic instability of colonic cellular
DNA [44–48]. However, as IBD comprises of heteroge-
neous population of subtypes, inter-individual variation
of gut microbiota and their expression potential among
similar population further complicates the generalization
and validation of bile acids needed to restore the bile
acid pool across IBD cohorts [49]. Hence, any deviation
from the physiological range of secondary BAs could
contribute to a disease phenotype.
The biological relevance of these secondary and ter-
tiary BAs, such as DCA, LCA, ursodeoxycholic acid
(UCDA) have known to be potent agonists for several
BA receptors and exert anti-inflammatory effects in the
colon. For instance, they bind to TGR5 and inhibit the
Fig. 5 Quantitative comparison of bile acid metabolites between healthy and IBD subjects of American cohort. The shape refers to the kernel probability
density of the data at different values. The pointrange refers to the mean and error range value of the data distribution. The asterisks on the top indicate
ns: p > 0.05, *: p <= 0.05, **: p <= 0.01, ***: p <= 0.001, ****: p <= 0.0001 (Mann-Whitney Wilcoxon test). IBD subjects diagnosed with subtype Crohn’s
disease and Ulcerative colitis is abbreviated as CD and UC respectively
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production of cytokines once encountered with lipopoly-
saccharides from gram-negative bacteria [50]. LCA could
also regulate adaptive immune responses via VDR signal-
ing [51] whereas FXR activation maintains the produc-
tion of BAs and their homeostasis [52]. These properties
of secondary BAs suggest their beneficial role in redu-
cing inflammation in IBD [53]. The importance of bile
acid therapy has been shown in animal studies and in
human-trials [54–58]. Of particular interest, UDCA,
which is an FDA-approved drug for cholestatic liver
disease, has been shown to ameliorate inflammation in
dextran sulfate sodium-induced colitis mice [59].
Considering the relation between BA metabolism and
IBD, one potential application using probiotics has alle-
viated disease remission of relapsing UC patients [60,
61]. To tolerate bile acid stress in the gut, the ability to
hydrolyze bile salts is often considered for probiotic
strain selection [20, 62]. Therefore, to improve the gut
health of IBD subjects, had they been supplemented with
BSH-active strain formulated in probiotics along with
their routine anti-inflammatory drug, synergistic effects
of this combination could help in the conversion of bile
salts to secondary BAs. This approach has improved the
clinical features of relapsing UC patients suggesting that
interventions targeting BA metabolism may have thera-
peutic implications [60, 61]. Reconstitution of gut micro-
biota with BSH-active species through fecal microbiota
transplantation has been effective in prevention of recur-
rent Clostridium difficle infection [36]. Overall, this
study further stresses that IBD-associated altered BA
biotransformation could remove anti-inflammatory ef-
fects of BAs and the dysbiotic state could participate in
the chronic inflammatory loop tipping towards an im-
munosuppressed state of health.
Conclusions
Taken together, our approach of targeted identifica-
tion and quantification of bile salt biotransformation
has enabled us to realize the impact of gut microbial
mediated metabolic effects on the host system. This
functional dysbiosis was observed in the gut micro-
biota of IBD individuals, who were in early-onset IBD
or clinical remission stage. We also observed that the
reduction of Firmicutes-specific bile acid-related genes
is in line with the compositional reduction of Firmi-
cutes (especially species with bile metabolic potential).
From a broad view of the omics lens, the metage-
nomic predictions and the metabolomics evaluations
were consistent in both approaches. However, verifica-
tion of identified homologs from few of the cultivable
species, through a reductionist approach, could fur-
ther verify the biological significance of sequence con-
servation. Nonetheless, gut microbial composition and
their function could potentially tip a compensated
state of immune balance in favor of chronic disease
in IBD hosts.
Methods
IBD cohort description
Shotgun metagenomes were obtained from European
Nucleotide Archive at EMBL-EBI under the accession
number PRJEB2054 and PRJNA389280.
From PRJEB2054, 14, 4, and 21 samples of Healthy
(H), Crohn’s disease (CD), and Ulcerative colitis (UC) re-
spectively were analyzed for differential BSBG abun-
dance analysis [63]. Both subtypes of IBD subjects were
in clinical remission for at least 3 months and had stable
maintenance therapy with mesalazine or azathioprine.
Individuals who were undergoing antibiotic treatment
for at least 4 weeks before fecal sample collection were
excluded [64].
From PRJNA389280, 18, 44, and 21 samples of
Healthy (H), Crohn’s disease (CD) and Ulcerative colitis
(UC) respectively were analyzed for differential BSBG
abundance and BA metabolite analysis. These samples
had paired or coordinated metagenomics and metabolo-
mics data available. None of these IBD subjects had a
history of terminal ileal resection. Detailed information
for the sample selection criteria on IBD subjects is avail-
able in the original article [30].
Bioinformatic identification of bile salt biotransformation
protein homologs
To identify BSBP homologs from the UniProt database
[65], experimentally verified BSBPs from Clostridium
scindens (strain JCM 10418 / VPI 12708) and other spe-
cies were deployed as query sequences (Additional file 1:
Table S1 and Figure S1). The selection process of BSBP
homologs was performed in two sections. First, screen-
ing the candidate BSBPs using BLASTp [66] under opti-
mal threshold parameters (Additional file 1: Table S2).
To determine the threshold for BLASTp search, protein
sequences with known BSB function and non-BSB func-
tion were used as test data. For instance, BSB proteins
from Eggerthella lenta was used as positive control [67,
68], while protein sequences from Helicobacter, Prevo-
tella, and Porphyromonas were used as negative control
[69–74]. The accuracy of BLASTp was estimated at dif-
ferent similarity thresholds with defined e-value and
coverage (Additional file 1: Table S2).
Using the BSH-specific HMM and PVA-specific HMM
[75, 76], protein sequences of bile salt hydrolase (BSH)
category were identified to make a distinct classification
from penicillin-v-acylase (PVA) enzyme sequences, as
both shared identical domain CBAH superfamily.
Sequences that had higher e-value in the BSH cluster
compared to that in the PVA cluster were selected for
further analysis.
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Secondly, the candidate BSBP homologs were searched
against the Pfam 31.0 database to identify their functional
domains using the default GA (gathering cut-offs) [77].
Sequences with identical domain organizations were
retained for the following analysis (Additional file 1: Table
S3). Additionally, homologous protein sequences that
were filtered across the Pfam domain analysis were
checked for their functional annotation using the eggNOG
algorithm [78] with DIAMOND as mapping mode and
other default parameters. Sequences that mapped to simi-
lar annotations to the reference protein were considered
for the final reference database. The taxonomic lineage of
the identified gene sequences was retrieved from the Uni-
Prot website (dated on October 2018) [65].
Construction of protein sequence similarity network
(PSSN)
An all-by-all protein BLAST was performed for all the
homologous sequences to be analyzed in the dataset.
Pairs of sequences with significant similarity were se-
lected through the application of a series of pairwise
protein BLAST e-value thresholds, where their distribu-
tion was used to define the optimal e-value cut-off. Sub-
sequently, significant alignments (with e-value less than
the optimal e-value and minimum of 30% pairwise simi-
larity) were used to construct the PSSN (Additional file
1: Table S4). Each node of the network indicates a pro-
tein sequence, and the edge represents the relatedness
between two nodes sharing significant similarity as de-
fined by the edge metric (i.e., e-value and percentage
identity). Networks were visualized with the ggnetwork
package in R [79, 80].
Functional metagenomic mapping
For quality assessment, publicly available fastq reads were
subjected to a quality check using FastQC [81] with a mini-
mum Phred score of 30. Each pair of fastq files was repaired
to remove the singletons (if needed) using the script avail-
able at (https://github.com/BioInfoTools/BBMap/blob/mas-
ter/sh/repair.sh). Bile salt biotransformation gene
abundances were calculated using FMAP [82] with the de-
fault parameters. Gene sequences that were binned into the
functional category of Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) pathway ko00121 were determined by map-
ping of UniRef to KEGG Orthologies (KOs) database [83,
84]. Then, the numbers of mapped reads were normalized
to the total number of paired reads in the metagenomes.
The taxonomic lineage for each mapped protein gene ID
sequence was obtained from UniProt database [85].
Statistical analysis
All the statistical analysis and graphics were performed
using R version 3.5.0 [86]. In each cohort, samples were
country-matched to avoid cross country-effects.
Normality of the given dataset was assessed through the
Shapiro–Wilk test. Differential abundance analysis be-
tween healthy and IBD subjects was tested using Mann-
Whitney-Wilcoxon tests (for comparison between two
groups), and Kruskal Wallis tests (for comparison
among three groups). Multivariable linear regression was
performed for age, BMI and gender on the gene abun-
dance to identify confounding variable (p < 0.01) by un-
adjusted analysis.
Additional files
Additional file 1: Table S1. List of query proteins and their basic
description used as reference sequences to identify bile acid metabolic
proteins (sourced from UniProt). Table S2. Optimal cut-off parameters
chosen to filter the significant sequence hits were determined based on
the distribution of BLAST pairwise percentage identity, e-value and query
and target coverage. Table S3. List of query proteins with the description
of their Pfam domain. Table S4. Optimal cut-off parameters chosen for
the construction of protein sequence-based similarity network were de-
termined based on the distribution of BLAST pairwise percentage identity
and e-value values. Figure S1. Schematic representation of a generalized
bile salt biotransformation pathway. Enzymatic proteins that were studied
have been highlighted in red color. Figure S2. The normalized abun-
dance of total BSBGs in healthy individuals sampled from the USA,
Denmark, and Spain. The Y-axis of the boxplot refers to the normalized
abundance, whereas the X-axis refers to the country of these healthy
control groups. The shape refers to the kernel probability density of the
data at different values. The asterisks on the top indicate ns: p > 0.05, *:
p < = 0.05, **: p < = 0.01, ***: p < = 0.001, ****: p < = 0.0001 (Mann-Whit-
ney Wilcoxon test). Figure S3. The normalized abundance of taxonomic-
lineage specific BSBGs in healthy and IBD subjects sampled from Spain.
The Y-axis of the violin plot refers to the normalized abundance, whereas
the X-axis refers to the diagnosis. The shape refers to the kernel probabil-
ity density of the data at different values. The pointrange refers to the
mean and error range value of the data distribution. The asterisks on the
top indicate ns: p > 0.05, *: p < = 0.05, **: p < = 0.01, ***: p < = 0.001, ****:
p < = 0.0001 (Mann-Whitney Wilcoxon test). (DOCX 413 kb)
Additional file 2: Table S1. Prevalence of bile salt biotransformation
protein homologs in bacterial strains, where numeric one and zero refers
to the presence and absence of the homolog. (XLSX 335 kb)
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